U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07371104) titled 'Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer' on Jan. 19.
Brief Summary: A Multicenter, Open-label, Randomized, Multi-dose, 2-sequence, 2-period, Crossover Bioequivalence Study to Comparison of the Pharmacokinetics and Safety of DWZ2501 and DWC202510 in Patients with Advanced BRCA-mutated High-grade Ovarian Cancer
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Cancer
Ovarian Cancer
Intervention:
DRUG: DWZ2501 (Olaparib 150mg)
Subjects receive 600 mg per day, two tablets BID (total 4 tablets), oral administration
DRUG: DWC202510 (Olaparib 150mg)
Subjects...